AstraZeneca breast melanoma drug trial tremendous - MarketWatch

LONDON--AstraZeneca PLC (AZN.LN) Friday introduced high quality effects from a section III trial of its breast melanoma medication Lynparza.

Metastatic breast melanoma sufferers treated with the drug "confirmed a statistically-colossal and clinically-meaningful improvement" in comparison with sufferers who obtained chemotherapy, AstraZeneca noted.

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan